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Abstract
Background: Under conditions of cardiovascular dysfunction, protease-activated receptor 2 (PAR2) agonists
maintain vasodilatation activity, which has been attributed to increased cyclooxygenase-2, nitric oxide synthase and
calcium-activated potassium channel (SK3.1) activities. Protease-activated receptor 2 agonist mediated
vasodilatation is unknown under conditions of dysfunction caused by angiotensin II. The main purpose of our
study was to determine whether PAR2-induced vasodilatation of resistance arteries was attenuated by prolonged
angiotensin II treatment in mice. We compared the vasodilatation of resistance-type arteries (mesenteric) from
angiotensin II-treated PAR2 wild-type mice (WT) induced by PAR2 agonist 2-furoyl-LIGRLO-amide (2fly) to the
responses obtained in controls (saline treatment). We also investigated arterial vasodilatation in angiotensin II-
treated PAR2 deficient (PAR2-/-) mice.
Results: 2fly-induced relaxations of untreated arteries from angiotensin II-treated WT were not different than saline-
treated WT. Treatment of arteries with nitric oxide synthase inhibitor and SK3.1 inhibitor (L-NAME + TRAM-34)
blocked 2fly in angiotensin II-treated WT. Protein and mRNA expression of cyclooxygenase-1 and -2 were increased,
and cyclooxygenase activity increased the sensitivity of arteries to 2fly in only angiotensin II-treated WT. These
protective vasodilatation mechanisms were selective for 2fly compared with acetylcholine- and nitroprusside-
induced relaxations which were attenuated by angiotensin II; PAR2-/- were protected against this attenuation of
nitroprusside.
Conclusions: PAR2-mediated vasodilatation of resistance type arteries is protected against the negative effects of
angiotensin II-induced vascular dysfunction in mice. In conditions of endothelial dysfunction, angiotensin II
induction of cyclooxygenases increases sensitivity to PAR2 agonist and the preserved vasodilatation mechanism
involves activation of SK3.1.
Background
The attenuation of endothelium-dependent vasodilata-
tion elicited by hormones or shear stress is a condition
observed in cardiovascular diseases. This condition is
often referred to as endothelial dysfunction. It is thought
that endothelial dysfunction is an early development in
the time course of cardiovascular diseases. Clinical tests
of patients for endothelial dysfunction include measur-
ing the vasodilator responses of blood vessels to an
agonist of the endothelium e.g. cholinergic agonist acet-
ylcholine. Protease-activated receptor 2 (PAR2) is a G
protein coupled receptor which can be activated by tryp-
sin-like serine proteases and PAR2-activating peptides
(PAR2-AP [1,2]. These peptides activate the endothe-
lium to cause acute vasodilatation, decrease blood pres-
sures and protect tissues from ischemia [3-5]. Studies in
genetic hypertension, stroke and diabetes have reported
that PAR2-AP vasodilatations were persistent despite
endothelial dysfunction being present [6-10]. The acute
mechanisms of action of PAR2-AP require further study
because these pathways represent elements of vascular
smooth muscle relaxation which are protected against
the negative effects of cardiovascular diseases.
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Under normal conditions PAR2-AP mediate acute vaso-
dilatation of small caliber resistance arteries via nitric
oxide and Ca2+-activated K+ channels (KCa) [11,12]. There
are a few variations in the mechanisms that have been
attributed to the PAR2-AP mediated vasodilatation
mechanisms during endothelial dysfunction. These
mechanisms have included the selective activation of
SK3.1 [6,10], endothelial nitric oxide synthase (eNOS) [8],
and cyclooxygenases (COX) [9]. In non-obese diabetes
models of endothelial dysfunction, increased PAR2 expres-
sion was reported [8,9]. The uncertainty in the mechan-
isms of PAR2 vasodilatation in endothelial dysfunction
may be due to the choice of experimental models particu-
larly the reliance on genetic strains of rodents. Human dis-
eases represent complex phenotypes so it is important to
investigate PAR2 in multiple experimental models.
Chronic angiotensin II (ANG II) infusion produces a
model of acquired hypertension and endothelial dys-
function in animals. It is also linked to pro-inflamma-
tion signaling pathways involving p38 mitogen activated
protein kinase and nuclear factor-B. These transcrip-
tion pathways are proposed to partly link ANG II recep-
tor signalling to changes in endothelial cell phenotype,
which include induction of cyclooxygenase (COX-1 and
COX-2). In endothelial cell culture conditions the p38
mitogen activated protein kinase and nuclear factor-B
pathways link cytokines to induction of PAR2 expres-
sion and are activated by PAR2-AP [13,14]. Interestingly,
the induction of COX-2 in endothelial cells in culture
enabled PAR2 to stimulate cells to produce PGI2, which
was proposed as being vasculoprotective [13].
To date the effect of chronic ANG II-induced endothe-
lial dysfunction on PAR2-AP vasodilatation is unknown.
We have described a trend for higher blood pressures in
PAR2 gene (par2) knockout mice (PAR2-/-) after two
weeks of ANG II infusion [15]. These results may be con-
sistent with the proposal of PAR2-mediated protection of
blood vessels against the negative effects of chronic ANG
II. The primary goal of this study was to determine the
effects of ANG II-induced endothelial dysfunction on
vasodilatation by PAR2-AP [2-furoyl-LIGRLO-amide, 2fly,
[3]]. We also tested whether par2 gene deficiency was pro-
tective against chronic ANG II-induced endothelial dys-
function in the vasculature. Our findings provide new and
significant additions to understanding vascular pharmacol-
ogy and important interactions with cardiovascular pathol-
ogy. Also, these findings highlight the potential for SK3.1
to be a potential pharmaceutical target for hypertension.
Results
Preserved PAR2-mediated relaxations of mesenteric
arteries in ANG II C57
To determine whether chronic ANG II treatment atte-
nuated the vasodilator effectiveness of PAR2, we
measured relaxations by the PAR2 activating peptide
2fly of mesenteric arteries contracted submaximally by
a1-adrenoceptor agonist (cirazoline). Chronic ANG II
did not reduce the effectiveness of PAR2 to cause vaso-
dilatation of arteries (Figure 1A). 2fly-mediated relaxa-
tions of arteries of ANGII C57 vs. saline C57 were the
same (Figure 1A, Table 1). These data indicated that
PAR2-mediated vasodilatation by 2fly was protected
against treatment by chronic ANG II. As we have
reported elsewhere [3,10] PAR2 was confirmed as being
the specific target of 2fly in the bioassay by our finding
that concentrations up to 3 μM of this peptide had no
effect on arteries from saline PAR2-/- and ANG II
PAR2-/- (P > 0.05, relaxations not different than 0, data
not shown).
Contributions of NOS to preserved PAR2-mediated
relaxations of mesenteric arteries in ANG II C57
In normal (par2 wild-type) mice it is well-established
that eNOS contributes by a small extent to PAR2-
mediated vasodilatation of small mesenteric arteries
[3,6,10-12]. To determine whether an increased contri-
bution by NOS to PAR2 activity could be attributed to
the preserved vasodilator effectiveness of PAR2, we
compared 2fly-induced relaxations in the absence (Fig-
ure 1A) and presence of L-NAME (Figure 1B). Treat-
ment of arteries with L-NAME inhibited 2fly-induced
relaxations compared with controls to the same extents
in saline and ANG II C57 (Table 1). These data indi-
cated there was not a significant change in endothe-
lium-derived NO elicited by 2fly in ANG II C57.
Contributions of COX to preserved PAR2-mediated
relaxations of mesenteric arteries in ANG II C57
Inhibitors of COX have no effect on PAR2-mediated vaso-
dilatations of C57 mesenteric arteries [10-12]. However,
chronic in vivo treatment with ANG II has been reported
to induce expression of cyclooxygenases in vascular tis-
sues. To determine whether de novo contribution of COX
to PAR2 activity could be attributed to preserved vasodila-
tor effectiveness of PAR2, we compared 2fly-induced
relaxations in the absence (Figure 1A) and presence of
COX inhibitors (Figure 1C-F). As expected, the 2fly CRC
of untreated arteries from saline C57 (Figure 1A, saline)
were not different in the presence of COX inhibitors (Fig-
ure 1C-F, saline). The potency of 2fly in ANG II C57 (Fig-
ure 1A, ANG II) was reduced by either nonselective or
selective COX isoform inhibitors (Figure 1C-F, ANG II).
Indomethacin (nonselective COX inhibitor) in the absence
(Figure 1C) and presence of L-NAME (Figure 1D) caused
rightward shifts of the 2fly CRC in ANG II vs. saline C57.
Similarly, COX-1 inhibitor (FR122047) rightward shifted
the 2fly CRC in ANG II C57 vs. saline C57. COX-2 inhibi-
tor (NS398) reduced the steepness (hill slope) of the 2fly
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CRC relationship in ANG II C57 vs. saline C57 (Figure 1F)
and thus, inhibited the effectiveness of 2fly at the low to
middle range of concentrations (0.1 nM to 10 nM).
To investigate whether a single metabolite of COX
activity could be attributed to the potency changes for
2fly, we compared responses in the absence and
presence of various receptor antagonists for prostanoids
and thromboxane A2. The results of these experiments
(bottom half of Table 1) did not support a role for any
specific metabolite in the actions of COX inhibitors on
2fly potency in ANG II C57. 2fly CRC in ANG II C57
vs. saline C57 (Table 1) were not different in the
Figure 1 NOS and COX inhibitor effects on PAR2 agonist-induced vasodilations in saline- and ANG II-treated C57. C57BL/6J (C57) mice
were pretreated with saline or angiotensin II (ANG II) for two weeks prior to experiments. Values are the mean ± SE (n = number of mice) for 2-
furoyl-LIGRLO-amide (2fly)-induced relaxations of second order mesenteric arteries contracted submaximally by cirazoline. Arteries were exposed
to inhibitors [100 μM L-NAME, 10 μM indomethacin, 100 μM L-NAME + 10 μM indomethacin, 3 μM NS398, 1 μM FR122047] for 20 min prior to
cirazoline. *P < 0.05, inhibitor treatment compared with controls (A, untreated) within same pump treatment in (B) Emax, -log EC50 [both pumps],
hill slope [saline], (D) Emax [both pumps], -log EC50 [ANG II], (E) -log EC50, and (F) hill slope. ** P < 0.05, inhibitor treatment in ANG II vs. saline in
(C) -log EC50, (D) -log EC50, Emax, (E) -log EC50 and (F) hill slope. Two-way ANOVA (pump treatment × inhibitors) followed by Bonferroni post hoc
test.
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presence of antagonists for PGI2 receptor (CAY10441),
PGE2 receptors (AH6809, L798106, L161982), and
thromboxane A2 receptor (SQ29548).
Contributions of SK3.1 to preserved PAR-mediated
relaxations of mesenteric arteries in ANG II C57
It has been demonstrated numerous times [6,11,12] that
combined inhibition of NOS, SK3.1, and SK2.2/2.3 is
required to block vasodilatation of normal mouse
mesenteric arteries by PAR2-activating peptides; and
acetylcholine. Recent work by us [10] indicated a pri-
mary role for SK3.1 in contributing to preserved PAR2
vasodilatation in obese diabetic mouse mesenteric
arteries. To determine the contribution of SK3.1 to the
vasodilatation mediated by PAR2 in ANG II C57, we
investigated 2fly-induced relaxations in the presence of
specific SK3.1 inhibitor TRAM-34, which was done in
the absence and presence of NOS inhibitor L-NAME.
Indeed treatment of arteries by SK3.1 inhibitor reduced
the effectiveness of 2fly in ANG II mice (Figure 2) and
when combined with pretreatment by L-NAME the 2fly
CRC in ANG II C57 was blocked compared with con-
trols (Figure 2).
ACh mediated vasodilatations in saline vs. ANG II and C57
vs. PAR2-/-
We determined ACh mediated vasodilatations of arteries
from saline and ANG II treatments of both C57 and
Table 1 2-fuoryl-LIGRLO-amide (2fly) concentration-response curves of mesenteric arteries from saline- and
angiotensin II-treated C57 mice
Treatment n -log EC50
(M)
Emax
(%)
Hill slope n -log EC50
(M) a d
Emax
(%) b d
Hill slope c f
Saline Angiotensin II
controls 48 8.3(0.1) 97(1) 2.1(0.1) 52 8.1(0.1) 96(1) 1.8(0.1)
L-NAME 12 7.8(0.2)i 90(2)j 1.9(0.6)j 24 7.8(0.1) j 85(2)i 1.3(0.2)
indomethacin 12 8.4(0.1) 96(1) 2.1(0.5) 17 7.9(0.1)h 93(1) 1.5(0.2)
L-NAME + indomethacin 10 8.0(0.1) 90(2)k 1.2(0.3) 18 7.4(0.1)g i 81(4)g i 1.3(0.2)
NS398 3 μM 5 8.2(0.4) 92(4) 2.3(0.3) 7 7.9(0.1) 93(2) 4.7(1.6)h i
FR122047 12 8.3(0.1) 96(1) 2.0(0.3) 15 7.8(0.1)h k 91(2) 1.7(0.3)
NS398 + FR122047 5 8.0(0.2) 92(2) 0.9(0.1) 8 8.0(0.2) 94(2) 2.4(0.4)
CAY10441 7 8.3(0.2) 96(2) 1.8(0.3) 7 8.0(0.1) 96(1) 2.2(0.4)
AH6809 + L798106 + L161982 6 8.5(0.3) 97(1) 1.5(0.3) 6 8.0(0.1) 96(1) 2.2(0.4)
SQ29548 4 8.5(0.2) 96(1) 0.8(0.2) 6 7.9(0.2) 93(2) 2.0(0.4)
NS398 0.3 μM 7 8.1(0.1) 98(1) 2.1(0.3) 6 7.8(0.1) 95(1) 2.4(0.6)
Values are mean(SE), n = number of mice. Variables were determined by curve fitting data points from cumulative drug concentration-responses relationships to
a four parameter logistic function. Treatments of arteries included antagonists of COX-1 (1 μM FR122047), COX-2 (0.3, 3 μM NS398), COX-1/2 (10μM
indomethacin), NOS (100 μM L-NAME), prostaglandin E
2
receptors (1 μM AH6809, 1 μM L798106, 0.1 μM L161982), prostaglandin I
2
receptor (0.1 μM CAY10441)
and thromboxane A
2
receptor (1 μM SQ29548). Comparisons were made by two-way ANOVA (pump × artery treatment) [aP < 0.0001, bP < 0.01, and cP < 0.05,
effect of pump treatment, dP < 0.0001, and eP < 0.0005, effect of artery treatment, fP < 0.01, interaction between pump and treatment] followed by Bonferroni
post hoc tests: gP < 0.01, and hP < 0.05, compared to same inhibitor treatment in saline pump group [horizontal]; iP < 0.001, jP < 0.01, and kP < 0.05, controls
compared to inhibitor within same pump treatment [vertical].
C57, C57BL/6J; Emax, maximum relaxation response where 100% is complete reversal of contraction.
Figure 2 Inhibition of PAR2 agonist-induced vasodilations in
ANG II C57 by pretreatment with SK3.1 inhibitor. C57BL/6J (C57)
mice were pretreated with angiotensin II (ANG II) for two weeks
prior to experiments. Values are the mean ± SE (n = number of
mice) for 2-furoyl-LIGRLO-amide 2fly-induced relaxations of ANG II
C57 second order mesenteric arteries contracted submaximally by
cirazoline. Arteries were exposed to inhibitors [10 μM TRAM-34, 100
μM L-NAME + 10 μM TRAM-34] for 20 min prior to cirazoline. *P <
0.05, Emax, 10 μM TRAM-34 and 100 μM L-NAME + 10 μM TRAM-34
compared to untreated (control) arteries, one-way ANOVA followed
by Bonferroni post hoc test. **P > 0.05, L-NAME + TRAM-34,
relaxations at each dose of 2fly compared to 0, one-sample t-test.
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PAR2-/- to reproduce previous reports of the negative
effects of ANG II treatment on endothelial cell function.
These experiments also assessed the protection attribu-
ted to PAR2-/- genotype against the negative effects of
ANG II. PAR2-/- genotype did not afford protection for
untreated arteries against the negative effects on
endothelial function of ANG II treatment (Figure 3A
(controls), Table 2). Vasodilatation by ACh of untreated
(control) arteries was decreased in ANG II vs. saline
treatments to the same extent in C57 vs. PAR2-/- (Figure
3A, Table 2).
We determined ACh mediated vasodilatations in the
absence and presence of L-NAME in C57 and PAR2-/-
to investigate the involvement of eNOS in these
responses. While eNOS contribution to ACh-mediated
vasodilatation was the same in saline C57 vs. saline
PAR2-/- (Figure 3B), there was less eNOS contribution
to ACh mediated relaxations in ANG II C57 vs. ANG II
PAR2-/- (Figure 3B). This was found in the observation
that L-NAME caused no further attenuation of ACh
relaxations in ANG II PAR2-/- (Figure 3B) compared
with untreated arteries of ANG II PAR2-/- (Figure 3A,
Table 2).
We tested ACh-mediated vasodilatations in the absence
and presence of COX inhibitors to determine the selectiv-
ity of their actions on the potency of endothelium-depen-
dent agonists in ANG II C57. These experiments indicated
that the COX inhibitors effects in ANG II C57 were affect-
ing selectively 2fly in our bioassays. Treatments of arteries
by indomethacin in the absence (Figure 3C) or presence of
L-NAME (Figure 3D) compared with controls (Figure 3A)
did not differentially affect ACh CRC in saline- vs. ANG
II-treated mice. In addition, ACh CRC were not signifi-
cantly affected by selective antagonists of COX-1, COX-2,
PGI2 receptor, and PGE2 receptors (Table 2).
We determined the effects of combined inhibition of
eNOS, sGC, SK2.3, SK2.3, and SK3.1 to confirm the
involvement of these elements in the residual ACh-
mediated vasodilatations. A combination of L-NAME,
ODQ, apamin plus TRAM-34 was sufficient to block
ACh CRC (P > 0.05, not different than 0, n = 3 in saline
C57, ANG II C57, saline PAR2-/-, ANG II PAR2-/-, data
not shown).
Nitroprusside relaxations of arteries
To test the sensitivity of vascular smooth muscle to NO,
nitroprusside-induced vasodilatations were determined.
Indeed nitroprusside, which spontaneously releases NO
and bypasses the endothelium, was slightly less potent
in ANG II C57 vs. saline C57 (Figure 4A). The nitro-
prusside CRC was shifted to the right in ANG II C57
vs. saline C57 (Figure 4A, Table 3). Surprisingly, we
found that PAR2 -/- genotype was protective against the
potency shift caused by ANGII. The nitroprusside CRC
were not different in ANG II PAR2-/- vs. saline PAR2-/-
(Figure 4B, Table 3).
To test for potential off-target effects of the various
inhibitors of COX on vascular smooth muscle sensitivity
Figure 3 Acetylcholine-induced vasodilatations in C57 and
PAR2-/- mice administered saline and ANG II. C57BL/6J (C57) and
protease-activated receptor 2 gene knockout (PAR2-/-) mice were
pretreated with saline or angiotensin II (ANG II) for two weeks prior
to experiments. Values are the mean ± SE (n = number of mice) for
ACh-induced relaxations of second order mesenteric arteries
contracted submaximally by cirazoline. Arteries were exposed to
inhibitors [100 μM L-NAME, 10 μM indomethacin, 100 μM L-NAME +
10 μM indomethacin] for 20 min prior to cirazoline. *P < 0.05, saline
vs. ANG II in (A, C) -log EC50 and Emax and (B) Emax. **P < 0.05,
inhibitor treatment compared with controls (A, untreated) within
same pump treatment. Comparisons by two-way ANOVA (inhibitor
treatments × pump) followed by Bonferroni post hoc test.
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to NO, nitroprusside-induced vasodilatations in the pre-
sence and absence of these inhibitors were determined.
The various inhibitors of COX and PGI2/PGE2 receptors
did not affect vascular smooth muscle sensitivity to NO of
the arteries. Nitroprusside CRC were not affected by the
presence of FR122047, NS398, CAY10441 and the combi-
nation of AH6809, L798106 and L161982 (Table 3).
Endothelium-dependence of vasodilators in saline C57
and ANG II C57 arteries
To determine whether ACh- or 2fly-induced relaxations
were due to direct activation of vascular smooth muscle
cells, the inner linings of mesenteric arteries were
damaged and then the effectiveness of the agonists were
assayed. As expected from previous work in various
mouse arteries [6,10,12], in both saline and ANG II C57
the ACh- and 2fly-induced relaxations were reduced to
effective 0 after being subjected to endothelium removal,
but nitroprusside relaxed these arteries [relaxation (%),
saline (n = 5)/ANG II (n = 4): ACh: 8 ± 5/3 ± 3; 2fly: 2
± 2/8 ± 6; nitroprusside: 98 ± 2/96 ± 3].
Contraction of arteries by cirazoline in PAR2-/- vs. C57
We determined the contractions of arteries by a1- adre-
nergic receptor agonist cirazoline after saline and ANG II
treatment of C57 and PAR2-/- to investigate the effect of
PAR2-/- genotype on vasoconstrictor agonist effectiveness.
These experiments also investigated the effects of ANG II
on arteries responses to cirazoline. Surprisingly, cirazoline
was a more potent vasoconstrictor in PAR2-/- than in C57.
ANG II treatments did not increase the vasoconstrictor
effectiveness of cirazoline in arteries of either strain. In sal-
ine PAR2-/- (n = 11) and ANG II PAR2-/- (n = 12) the cira-
zoline CRC were shifted to the left (more potent) of saline
C57 (n = 27) and ANG II C57 (n = 33), respectively [***P
< 0.0005, two way ANOVA effect of strain on -logEC50:
saline PAR2-/-, 7.7 ± 0.1; ANG II PAR2-/-, 7.7 ± 0.1; saline
C57, 7.4 ± 0.1; ANG II C57, 7.4 ± 0.1].
PAR2-AP 2fly and acetylcholine under baseline conditions
in C57 and PAR2-/-
To determine whether the chronic ANG II treatment
induced a potential for vasoconstrictor activity by 2fly
and ACh, we measured isometric tension of mesenteric
arteries after exposing tissues to agonists. We found no
evidence of vasoconstrictor activity for these agonists in
the mesenteric arteries. There were no observed changes
in tension at baseline after the addition of either 2fly (up
to 10 μM) or acetylcholine (up to 300 μM) to arteries
from saline C57 (n = 3), ANG II C57 (n = 3), saline
PAR2-/- (n = 3) and ANG II PAR2-/- (n = 3).
mRNA expression of COX-1, COX-2, and PAR2
To determine whether mRNA expression of COX-1,
COX-2 and PAR2 were increased by ANG II treatment
of mice, we measured the mRNA expression pattern of
Table 2 Acetylcholine concentration-response curves of mesenteric arteries from saline- and angiotensin II-treated
mice.
Treatment i Strain n -log EC50
(M)
Emax
(%)
Hill slope n -log EC50
(M) a
Emax
(%) b c
Hill slope
Saline Angiotensin II
Controls C57 47 7.5(0.1) 90(1) 1.0(0.1) 52 7.0(0.1) 78(3)d 1.0(0.1)
PAR2-/- 14 7.7(0.1) 91(2) 1.0(0.1) 13 7.5(0.3) 77(5) 0.9(0.2)
L-NAME C57 13 7.5(0.2) 63(5)e f 0.7(0.1) 19 6.8(0.3) 49(5)g h 0.7(0.1)
PAR2-/- 8 7.2(0.3) 67(8)e f 0.7(0.1) 6 7.4(0.3) 68(13) 1.1(0.2)
indomethacin C57 8 7.4(0.2) 96(2) 1.5(0.6) 14 7.3(0.2) 81(4) 0.8(0.1)
PAR2-/- 8 7.5(0.3) 87(3) 1.0(0.1) 7 7.6(0.1) 76(8) 0.9(0.2)
L-NAME + indomethacin C57 12 7.3(0.3) 70(6)e f 0.8(0.2) 15 7.6(0.4) 59(6)g h 0.6(0.1)
PAR2-/- 7 7.7(0.2) 69(10)e 0.7(0.1) 5 7.4(0.2) 66(8) 0.6(0.1)
FR122047 C57 7 7.5(0.1) 87(3) 1.1(0.1) 11 6.9(0.3) 71(6) 1.5(0.8)
NS398 C57 8 7.7(0.3) 89(3) 1.3(0.3) 10 7.2(0.3) 78(8) 0.7(0.1)
FR122047 + NS398 C57 3 7.5(0.3) 75(4) 1.0(0.5) 7 7.4(0.2) 74(8) 1.3(0.3)
AH6809 + L798106 + L161982 C57 6 7.5(0.2) 90(3) 1.2(0.2) 6 6.8(0.2) 91(3) 1.2(0.3)
CAY10441 C57 7 7.4(0.2) 88(3) 1.0(0.1) 7 6.8(0.3) 86(3) 1.1(0.3)
Values are mean (SE), n = number of mice. Variables were determined by curve fitting data points from cumulative drug concentration-responses relationships to
a four parameter logistic function. Treatments of arteries included antagonists of COX-1 (1 μM FR122047), COX-2 (0.3, 3 μM NS398), COX-1/2 (10 μM
indomethacin), NOS (100 μM L-NAME), prostaglandin E
2
receptors (1 μM AH6809, 1 μM L798106, 0.1 μM L161982), prostaglandin I
2
receptor (0.1 μM CAY10441).
Comparisons were made by two-way ANOVA (pump × artery treatment) [aP < 0.05, bP < 0.0001, effect of pump (saline vs. angiotensin II), cP < 0.001, effect of
artery treatments] followed by Bonferroni post hoc tests: dP < 0.05, ANG II C57 controls compared to saline C57 controls; eP < 0.05, inhibitor group compared
with saline C57 controls; fP < 0.05, inhibitor group compared with saline PAR2-/- controls; gP < 0.05, group compared with ANG II C57 controls; hP < 0.05, inhibitor
group compared with ANG II PAR2-/- controls; i data from PAR2-/- were included as artery treatment factor for analyses.
C57, C57BL/6J; Emax, maximum relaxation response where 100% is complete reversal of contraction; PAR2
-/-, protease-activated receptor 2 gene knockout mice.
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these genes by real-time PCR. COX-2 mRNA expression
(normalised to triad gene reference) was significantly
upregulated in ANG II C57 (Table 4). COX-1 and PAR2
mRNA expression (normalised to triad gene reference)
were not significantly different between treatments.
Given the effectiveness of 2fly was reduced by COX
inhibitors in ANG II C57 (Figure 1C-F) and these PAR2
mediated relaxations were endothelium-dependent, we
also normalized the mRNA for COX-1 and COX-2 rela-
tive to par2 reference to relate mRNA expression to the
functional observations. According to this analyses,
COX-1 and COX-2 mRNA (normalised to par2) were
significantly upregulated in ANG II C57 (Table 4).
To determine whether the PAR2-/- genotype affected
the constitutive expression of COX-1/2 we compared
the gene expression pattern in C57 with PAR2-/-. COX-
1 and COX-2 mRNA were not significantly different
between PAR2-/- and C57 [ratio PAR2-/- (n = 4) to C57
(n = 4), P > 0.05, COX-1, 1.1 (0.7 - 1.4); COX-2, 1.1
(0.7 - 1.8)].
Protein expression of COX isoforms in mesenteric arterial
beds
To determine whether upregulated COX mRNA expres-
sion patterns and effectiveness of COX inhibitors were
matched to increased levels of COX proteins in arteries,
we measured the levels of COX proteins by Western
blot. The ratio of COX-2 to COX-1 protein expression
in mesenteric arterial beds was significantly higher in
ANG II C57 vs. saline C57 (Figure 5).
Discussion
Our main finding was the PAR2-AP vasodilatation of
small caliber arteries was protected against the negative
effects of chronic ANG II infusion. Activation of SK3.1
was critical to the mechanism of PAR2 mediated relaxa-
tions in ANG II mice. ANG II infusion in mice attenu-
ated NO-dependent relaxations by ACh and increased
the ratio of COX-2 to COX-1 protein expression. Inhi-
biting either COX-1 or COX-2 decreased the potency of
2fly in ANG II-treated mice. ANG II treatment did not
increase PAR2 expression in arteries. The PAR2-AP-
mediated acute vasodilatation during ANG II infusion
involves components of smooth muscle relaxation path-
ways that are resistant to the negative effects of
endothelial dysfunction in cardiovascular disease. These
components may be potential therapeutic targets for
protection against the consequences of cardiovascular
disease.
Inhibition of SK3.1 and endothelial NO synthase was
sufficient to block PAR2-AP mediated vasodilatation.
However, we found that chronic ANG II infusion of
mice also led to a change in PAR2 mediated relaxations
of vascular smooth muscle from indomethacin-insensi-
tive to indomethacin-sensitive. These finding suggest
COX is part of a minor supplementary mechanism of
action for PAR2 after ANG II treatment. In human
volunteers, aspirin treatment decreased the PAR2-AP
vasodilatation of forearm blood vessels [16]. In non-
obese diabetic mice, a selective COX-2 inhibitor
decreased the effectiveness of PAR2-AP on aortas [9].
This attenuation of PAR2-AP became larger as the
effectiveness of ACh decreased and the mice developed
hyperglycemia with age [9]. Under cell culture condi-
tions, exposure to PAR2 agonists increase COX-2
mRNA, protein and PGI2 [13,17] in endothelial cells.
We found either FR122047 (selective COX-1 inhibitor)
Figure 4 Nitroprusside-induced vasodilatations in C57 and
PAR2-/- mice administered saline and ANG II. C57BL/6J (C57) and
protease-activated receptor 2 gene knockout (PAR2-/-) mice were
pretreated with saline or angiotensin II (ANG II) for two weeks prior
to experiments. Values are the mean ± SE (n = number of mice) for
nitroprusside-induced relaxations of second order mesenteric
arteries contracted submaximally by cirazoline. Arteries were
exposed to inhibitors for 20 min prior to contraction by cirazoline
and the cumulative addition of nitroprusside. Relaxation (%)
represents the reversal of the contraction. *P < 0.05, saline C57 vs.
ANG II C57 in -log EC50. Comparisons by two-way ANOVA (pump ×
inhibitors) followed by Bonferroni post hoc test.
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or NS398 (selective COX-2 inhibitor) was sufficient to
decrease the potency of 2fly in ANG II-treated mice.
Antagonists of PGI2 and PGE2 receptors in our study
did not replicate the effects of COX inhibitors. There-
fore, it appeared that PGI2 and PGE2 receptors were not
involved with the supplementary mechanism.
We speculate that PAR2 activates COX-dependent
production of vasodilator reactive oxygen species, which
would be independent of prostaglandin receptors. In our
study, ANG II infusion reduced the potency of nitro-
prusside in arteries. Other studies have attributed the
attenuation of nitroprusside to quenching of the NO by
free radicals. In human vein endothelial cells, PAR2-AP
increased reactive oxygen species production from mito-
chondrial complex III and lesser amounts from COX-2
[18]. It has been reported that COX-dependent reactive
oxygen species [19] could activate big KCa which is
expressed on vascular smooth muscle. This would be
consistent with our interpretation that COX inhibitors
had an indirect effect on the PAR2 relaxations.
Our study highlights that the experimental model of
cardiovascular disease impacts the mechanisms of PAR2
action in blood vessels [6,7,20]. Albeit our study focused
on a small caliber artery which is used to model the
resistance vasculature and thus, uses less NO than large
caliber conductance type (e.g. femoral arteries, aortas)
for endothelium-dependent relaxations by PAR2 [12,21].
In other genetic hypertension models, the PAR2 vasodi-
latation of small caliber arteries was not linked to COX
[7,20]. Also, our current and previous studies indicate
that persistent PAR2 vasodilatation is entirely endothe-
lium-dependent. However, in non-obese diabetic mice
aortas and spontaneously hypertensive rat basilar
arteries the PAR2-AP vasodilatations were endothelium-
independent [9,22]. On the other hand, the central role
of SK3.1 has been highlighted as a common finding in
all of our studies on small caliber arteries. We reported
that in obese diabetic mice that SK3.1 was the key link
in the preserved PAR2 mediated vasodilation [10].
Recent studies have demonstrated the utility of targeting
SK2.2, SK2.3 and SK3.1 agonists for modulating vascular
tone, presumably by endothelium-dependent hyperpolar-
ization, and lowering blood pressure in ANG II-induced
hypertensive mice [23]. The protection of the PAR2
vasodilatation against ANG II-acquired hypertension
suggests that endothelial KCa activation by selected
membrane receptors could also provide the vasculature
with the ability to compensate or replace NO during
disease. Some investigators have reported that
uncoupled endothelial NO synthase may contribute to a
superoxide-mediated vasodilatation of aortas during
endothelial dysfunction in diabetes, which was also pro-
posed to be linked to ANG II [24]. However, inhibition
of uncoupled endothelial NO synthase by L-NAME
Table 3 Nitroprusside concentration-response curves of mesenteric arteries from saline- and angiotensin II-treated
mice
Treatments Strain n -logEC50
(M)
Emax
(%)
Hill slope n -logEC50
(M) a
Emax
(%)
Hill slope
Saline Angiotensin II
Control C57 27 7.7(0.1) 95(1) 0.9(0.1) 36 7.4(0.1)b 94(2) 1.2(0.1)
control c PAR2-/- 13 7.6(0.2) 96(1) 0.9(0.3) 10 7.7(0.2) 96(1) 1.0(0.3)
NS398 C57 7 7.8(0.3) 94(2) 1.3(0.4) 11 7.3(0.2) 95(1) 1.7(0.4)
FR122047 C57 9 7.7(0.2) 95(3) 1.1(0.2) 11 7.2(0.2) 94(2) 1.3(0.3)
AH6809 + L798106 + L161982 C57 5 7.4(0.2) 95(2) 1.3(0.5) 4 7.9(0.1) 96(1) 2.2(1.0)
CAY10441 C57 6 7.9(0.2) 96(1) 1.2(0.4) 5 7.4(0.3) 96(1) 1.7(0.8)
Values are mean (SE), n = number of mice. Variables were determined by curve fitting data points from cumulative drug concentration-responses relationships to
a four parameter logistic equation. Treatments of arteries included antagonists of COX-1 (1 μM FR122047), COX-2 (3 μM NS398), prostaglandin E2 receptors (1 μM
AH6809, 1 μM L798106, 0.1 μM L161982), prostaglandin I2 receptor (0.1 μM CAY10441). Comparisons were made by two-way ANOVA (pump × artery treatments)
[aP < 0.05, effect of pump (saline vs. angiotensin II)] followed by Bonferroni post hoc tests: bP < 0.05, control compared to saline pump treatment; cdata of control
arteries from PAR2-/- were included as a treatment factor for analyses.
C57, C57BL/6J mice; Emax, maximum relaxation response where 100% is complete reversal of contraction; PAR2
-/-, protease-activated receptor 2 gene knockout
mice.
Table 4 Protease-activated receptor 2, cyclooxygenase-1
and cyclooxygenase-2 mRNA expression in angiotensin
II- and saline-treated mice
mRNA Ratio
(angiotensin II to saline)
normalised to
triad
normalised to
par2
protease-activated receptor 2 0.6 0.2-1.8
cyclooxygenase-1 1.5 0.5-4.5 2.4b 1.2-4.2
cyclooxygenase-2 2.9a 0.6-16 4.5c 0.9-26
mRNA expression in mesenteric arterial cascades from mice was determined
by real-time PCR and normalised to triad housekeeping, and to protease-
activated receptor 2 genes (par2).
angiotensin II (ANG II) C57, n = 12; saline C57, n = 11.
Values reported are the mean and SE range (mean minus lower SE and mean
plus upper SE).
aP < 0.05, bP < 0.001, cP < 0.0005, gene upregulated in ANG II C57 compared
with saline C57. See Methods for details of statistical analyses.
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remains a point of controversy [25,26] so it is uncertain
whether a similar connection between PAR2 and
uncoupled endothelial NO synthase exists in the ANG
II infusion model.
The results of experiments in PAR2-/- indicate that
par2 null genotype had mixed effects on the negative
outcomes of ANG II infusions on blood vessels. First,
there was an increased sensitivity of arteries to
adrenergic receptor stimulation in PAR2-/-. Second,
there was less L-NAME sensitive endothelial NO-
derived relaxation activity (ACh-induced) in PAR2-/-
after treatment with ANG II. Third, the potency of
nitroprusside in ANG II PAR2-/- was not decreased as
in ANG II C57. The first of the effects above would be
expected to increase systolic and pulse pressures in
PAR2-/-. The second and third effects mentioned could
Figure 5 Expression of COX-1 and COX-2 in saline C57 and ANG II C57 mesenteric arteries. C57BL/6J (C57) mice were pretreated with
saline or angiotensin II (ANG II) for two weeks prior to experiments. Upper panel (A) summarises protein densitometry data collected from four
saline C57 and four ANG II C57 for COX-1 and COX-2. Protein expression ratios (COX-2 to COX-1) were determined from the target bands
normalised to the densities of GAPDH. **P < 0.005, saline vs. ANG II, Student’s t-test for unpaired data. Lower panels (B - E) show representative
data collected from two saline C57 and two ANG II C57 mice indicating immunoreactive bands corresponding to (B) COX-1, (D) COX-2, and after
stripping and re-probing membranes, the bands corresponding to (C, E) GAPDH. Each sample was assayed in duplicate at the protein amounts
indicated in each lane. Internal reference protein (vas deferens) and relative molecular weight ladder (MW) are also shown. Pen marks indicate
the location of prestained MW, which were transcribed by overlay of films on membranes.
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be interpreted as protective compensatory mechanisms
that may limit increases in blood pressures in PAR2-/-.
Our radiotelemetry study of blood pressures indicated
that by the end of treatment period, ANG II produced
larger systolic and pulse pressure changes in PAR2-/-
than in C57 [15]. A limitation to the scope of our study
was the focus on disruption by ANG II of endothelium-
dependent vasodilatation. We examined only one vaso-
constrictor system, necessarily to establish conditions
for bioassay, so it was possible that PAR2-/- may have
affected vasoconstrictor systems other than a1 adrener-
gic receptors e.g. 5-hydroxytryptamine, thromboxane A2
[27]. In the past 10 years, the literature weighs heavily
with evidence linking activated PAR2 to pro-inflamma-
tory signal transduction in endothelial cells [28]. There
is also a broad literature contending that chronic ele-
vated levels of ANG II elicits increased pro-inflamma-
tory signalling by cytokines and pro-thrombotic
conditions that contribute to the disruption of normal
endothelial and vascular smooth muscle cell biology
[29]. In wild-type animals, it is possible that increased
activity of coagulation factors and or other serine protei-
nases during chronic ANG II infusion leads to PAR2
activation and thus, the production of cytokines that
cause vascular dysfunction. Accordingly, it would be
expected that the production of pro-inflammatory med-
iators elicited by ANG II in par2 null mice may be atte-
nuated and thus, the disruptions by ANG II of the
endothelium and vascular smooth muscle are reduced.
Conclusions
PAR2-AP effectiveness is protected against the negative
effects of ANG II. par2 null expression had mixed
effects in vitro on the negative outcomes of ANG II
hypertension. The preserved PAR2 vasodilatation which
is mediated largely via SK3.1 may lead to discovery of
other endothelial cell signaling that is resistant to vascu-
lar diseases.
Methods
Animals
Control (par2 wild-type) mice (C57BL/6J, C57) and par2
gene deficient mice (PAR2-/-; B6.Cg-F2rl1tm1mslb/J) were
purchased from the Jackson Laboratories (Bar Harbor,
ME). Genotypes of PAR2-/- were confirmed by PCR
using specific primer sets as per supplier’s protocol [30].
Male mice (10-30 weeks of age; 25-32 g) were fed a
standard regular salt feed (NIH-31 autoclavable open
formula mouse diet; Zeigler Bros Inc., Gardners, PA,
USA) and provided water ad libitum while housed indi-
vidually in air filter-topped cages in a room of the Ani-
mal Care Facility. All protocols were approved by the
Institutional Animal Care Committee of Memorial Uni-
versity in accordance with the guidelines and principles
for use of animals in research by the Canadian Council
on Animal Care.
Sources of drugs and reagents for myograph studies
Unless stated otherwise, all drugs and reagents were
obtained from Sigma Aldrich (Oakville, Ontario,
Canada). Other sources included: Tocris BioScience
(Ellisville, MO, USA), FR122047, CAY10441, AH6809,
L798106, L161982, NS398, SQ29548; Toronto Research
Chemicals (Toronto, Ontario, Canada), TRAM-34; Pep-
tides International (Louisville, KT, USA), 2-furoyl-leu-
ile-gly-arg-leu-orn-amide (2fly). Stock solutions of indo-
methacin, TRAM-34, ODQ, FR122047, CAY10441,
AH6809, L798106, L161982, NS398 and SQ29548 were
made in dimethylsulfoxide and added as a 1/1000 dilu-
tion to tissue bath solutions. Stock solutions of all other
drugs were made in water.
Chronic ANG II infusion
On day 0 of the ANG II infusion protocol, a micro-
osmotic pump (ALZET model 1002, Durect Corp.,
Cupertino, CA, USA) containing either isotonic saline
(0.25 μl/h) or ANG II (1 μg Ile5-angiotensin kg-1 min-1)
was implanted dorsally subcutaneously. Mice underwent
surgeries to implant the micro-osmotic pumps (~10-15
min) using isoflurane/oxygen anesthesia, followed by
monitoring their recovery for 4-6 h before being
returned to their home cages. Twelve to 14 days later
mice were anaesthetised with isoflurane and then killed
by cervical dislocation. In a subset of these mice, blood
pressures were recorded by radiotelemetry methods
which we reported previously [15].
Relaxation bioassays
To test the effect of chronic ANG II on endothelial
function and the influence of PAR2-/-, the vasodilatation
of small caliber mesenteric arteries from ANG II-treated
mice were compared to the responses in saline-treated
mice. Twelve to 14 days after implanting a micro-osmo-
tic pump, a mouse was killed and their mesenteric
arcades with attached adipose, blood vessels and nerves
were dissected free from gastrointestinal tract in situ
and immediately place in ice-cooled Krebs buffered
bicarbonate solution (114 mM NaCl, 4.7 KCl, 0.8 mM
KH2PO4, 1.2 mM MgCl2, 2.5 mM CaCl2, 25 mM
NaHCO3 and 11 mM D-glucose). Rings of second order
mesenteric arteries (2-12 per mouse) of 1-2 mm lengths
were isolated from arcades and positioned in small wire
myograph chambers (DMT 610 M, DMT 620 M) for
measurement and recording of isometric tension as
described [6,10]. Each chamber contained Krebs buf-
fered solution (pH 7.4) bubbled with 95% O2/5% CO2 at
37°C. Initial resting tension for each artery was deter-
mined as described [6], with initial effective pressure at
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7.98 kPa. After an initial equilibration period (1 h), vas-
cular reactivity was measured. Tissues were deemed
viable when the addition of 90 mM potassium chloride
produced a tension change > 1 mN/mm length. In
artery rings from each of the four treatment groups (sal-
ine C57, saline PAR2-/-, ANG II C57, ANG II PAR2-/-),
contractions were determined from cumulative additions
of cirazoline (1 nM-3 μM) to the baths. To determine
the relaxation response, the rings were contracted by
addition of small increments of cirazoline to submaxi-
mal tensions [50-80% of Emax], even in the presence of
inhibitors, based on concentration-response curves
(CRC) data. After a stable contraction was obtained, a
PAR2-activating peptide, 2fly (0.1 nM-3 μM) [3], ACh
(1 nM-10 μM) or nitroprusside (0.1 nM-100 μM) was
added cumulatively to the bath. The order of vasodilator
agonist addition was determined in a randomly assigned
order. The contraction and relaxation responses were
measured in either the absence or presence of inhibitors
(20 min), which included NG-nitro-L-arginine methyl
ester (L-NAME, NOS inhibitor, 100 μM), indomethacin
(COX-1/2 inhibitor, 10 μM), ODQ (soluble guanylyl
cyclase (sGC) inhibitor, 1 μM), apamin (SK2.2/2.3 inhi-
bitor, 1 μM), TRAM-34 (SK3.1 inhibitor, 10 μM),
NS398 (COX-2 inhibitor, 0.3, 3 μM), FR122047 (COX-1
inhibitor, 1 μM), CAY10441 (PGI2 receptor antagonist,
0.1 μM), PGE2 receptors antagonists combination
[AH6809 (1 μM), L798106 (1 μM), L161982 (0.1 μM)],
and SQ29548 (thromboxane A2 receptor antagonist, 1
μM). Inhibitor treatment with these antagonists were
reported as being effective [6,31-37]. Endothelium-
dependence of relaxation by the test agonists was deter-
mined by pulling a human hair through the lumen of
arteries and then assaying the agonists [10].
mRNA expression
mRNA expression was assayed in mesenteric arterial
arcades using quantitative real-time PCR methods as
described [10]. Extraction and purification of total RNA
from frozen tissues followed the manufacturer’s instruc-
tions (Qiagen, Mississauga, Ontario, Canada). TaqMan
RNA-to-CT 1-step kit procedures were followed according
for real-time measurement of target gene expression on an
ABI Prism 7000 light cycler (Applied Biosystems, Foster
City, CA, USA). For each target gene primer-fluorescent
probe set the amount of RNA used was optimized. Gene
specific primer-fluorescent probe sets were available com-
mercially (Applied Biosystems, assay/product ID: COX-1,
Mm00477214_m1; COX-2, Mm00478374_m1; PAR2,
Mm00433160_m1; glyceraldehyde 3-phospate dehydro-
genase, GAPDH, 4352932E; b2-microglobulin,
Mm00437762_m1; calnexin, Mm00500330_m1; Streets-
ville, Ontario, Canada). The primer-fluorescent probe sets
were validated for par2 and the other genes, previously
[10]. In some instances to accommodate low individual
yield of samples, RNA was pooled from two to three mice
and each pooled set was treated as one independent sam-
ple. Each sample was measured in duplicate. A triad refer-
ence gene expression approach (GAPDH, b2-
microglobulin, calnexin) was used from normalization of
sample material, and the efficiencies for primer sets for
each were included in all calculations.
Protein expression in whole mesenteric arteries
Western blots were performed on mesenteric arterial
protein following the same procedures as described [10].
To accommodate low individual yield of arterial protein
from each mouse, protein was pooled from up to three
mice to obtain each independent tested sample. Mem-
branes were probed separately with specific primary
antibodies against COX-1 (#160109, Cayman Chemicals,
Ann Arbor, MI, USA), COX-2 (SC-1745, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and GAPDH (SC-
25778, Santa Cruz Biotechnology). As positive controls
for both COX-1 and COX-2 detection, 500 ng of total
protein isolated from mouse vas deferens was loaded in
separate wells [38]. Immunoreactive bands on mem-
branes were visualized on x-ray film by chemilumines-
cence detection according to supplier (Super-Signal
West Pico, Thermo Fisher Scientific Inc., Rockford, IL,
USA). Image J (National Institute of Health, Bethesda,
MD, USA) software was used to quantify target band
intensities. Representative immunoblots of experiments
were repeated independently three times.
Data Analyses
Individual CRCs were analysed by nonlinear regression
curve fitting of drug concentration-relaxation/contrac-
tion response relationships using a four parameter logis-
tic function. We compared the variables of negative log
EC50, Hill slope and Emax values between groups by
one-way or two-way (pump × artery treatment)
ANOVA as indicated in the legends of Figures and
Tables. Statistics indicating significant main effects or
interactions were followed by Bonferroni post hoc for
multiple comparison testing. As indicated in legends to
Figures, the data points at each cumulative drug concen-
tration were compared to a hypothetical value of 0 by
one-sample t-test when data points from individual CRC
did not fit a logistic function (R2 < 0.8). *P < 0.05 was
considered significant. Myograph data were reported as
mean ± SE, and n = number of mice. For protein
expression data, target band density in each lane was
normalised to the corresponding density for GAPDH
then the COX-2 to COX-1 ratio for each sample was
determined. Protein data are reported as mean ± SE,
and n = number of independent samples. Comparisons
of COX-2 to COX-1 ratio were made by Student’s t-test
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for unpaired data. *P < 0.05 was considered significant.
In mRNA expression experiments, group-wise compari-
son of relative expressions and statistical analyses of the
relative expression results from real-time PCR were
done using REST 2008 software [39] with data com-
bined from 1 to 4 independent experimental runs. Data
are reported as the mean and SE interval for the ratio of
ANG II to saline normalised target genes expression
where n = number of independent samples. *P < 0.05
was considered significant.
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